These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15322234)

  • 1. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
    Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
    Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure.
    Leontiou C; Watters GP; Gilroy KL; Heslop P; Cowell IG; Craig K; Lightowlers RN; Lakey JH; Austin CA
    Mol Pharmacol; 2007 Apr; 71(4):1006-14. PubMed ID: 17209120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
    Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
    Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    Nitiss JL; Vilalta PM; Wu H; McMahon J
    Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
    Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
    Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
    Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
    Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
    DeVore RF; Corbett AH; Osheroff N
    Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
    Nitiss JL; Liu YX; Hsiung Y
    Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
    Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
    Jiang X
    Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR; Foster SR; Maxwell A
    J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Wasserman RA; Wang JC
    Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
    Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
    Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.